> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncology Center Reports on Progress
- URL: https://www.fdaweb.com/oncology-center-reports-on-progress/
- Published: 2019-03-27T12:00:00.000Z
- Updated: 2026-09-15T01:16:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5143714

The FDA Oncology Center of Excellence (OCE) 2018 [annual report](https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OCE/UCM634010.pdf?ref=fdaweb.com) describes steps taken to get the Center up and running since its 1/2017 establishment as authorized by the 21st Century Cures Act. Director **Richard Pazdur** writes that OCE “has collaborated with FDA’s medical products Centers to expedite many important clinical reviews, including the first two chimeric antigen receptor T-cell therapies for the treatment of advanced hematologic malignancies, and the first approvals of site-agnostic indications. The OCE also created two pilot programs to improve the process of evaluating data and evidence to generate a benefit-risk assessment which informs regulatory decisions: the Real-Time Oncology Review and the Assessment Aid. Our experts have led the development of 12 guidance documents on important aspects of oncology and malignant hematology product development.”

Discussing the need to collaborate with stakeholders, Pazdur says OCE has held more than 60 symposiums bringing academics and key therapeutic leaders to FDA. And it has held two workshops for patient advocates to discuss the important role they can play in oncology product development.